0000899243-22-035451.txt : 20221109 0000899243-22-035451.hdr.sgml : 20221109 20221109170511 ACCESSION NUMBER: 0000899243-22-035451 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221107 FILED AS OF DATE: 20221109 DATE AS OF CHANGE: 20221109 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Subramaniam Somu CENTRAL INDEX KEY: 0001508910 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40928 FILM NUMBER: 221373600 MAIL ADDRESS: STREET 1: C/O ICAD INC STREET 2: 98 SPIT BROOK ROAD SUITE 100 CITY: NASHUA STATE: NH ZIP: 03062 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Ventyx Biosciences, Inc. CENTRAL INDEX KEY: 0001851194 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 832996852 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 662 ENCINITAS BLVD., STE. 250 CITY: ENCINITAS STATE: CA ZIP: 92024 BUSINESS PHONE: (858) 945-2393 MAIL ADDRESS: STREET 1: 662 ENCINITAS BLVD., STE. 250 CITY: ENCINITAS STATE: CA ZIP: 92024 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-11-07 0 0001851194 Ventyx Biosciences, Inc. VTYX 0001508910 Subramaniam Somu C/O VENTYX BIOSCIENCES, INC., 662 ENCINITAS BLVD, SUITE 250 ENCINITAS CA 92024 1 0 1 0 Common Stock 2022-11-07 4 S 0 3935 29.0794 D 16888593 I See Footnotes Represents the weighted average share price of an aggregate total of 3,935 shares sold in the price range of $29.00 to $29.20. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Consists of (i) 5,873,225 shares held by NSV Investments I, LP, (ii) 2,295,172 shares held by NSV Master Limited Partnership II, LP, (iii) 2,023,131 shares held by NSV 2019 Opportunities Fund, LP, (iv) 1,760,420 shares held by NSV 2018 New Horizons Fund, LP, (v) 1,323,264 shares held by Life & Tech, (vi) 1,179,921 shares held by NSV Investments III, LP, (vii) 998,099 shares held by NSV Investments II, LP, (viii) 434,423 shares held by New Science Ventures, LLC, (ix) 272,484 shares held by NSV Growth Opportunities Fund, LP, (x) 213,533 shares held by New Science Ventures Fund III, LP, (xi) 187,679 shares held by NSV 2017 Opportunities Fund, LP, (xii) 130,872 shares held by NSV 2018 Opportunities Fund, LP, (xiii) 101,221 shares held by NSV 2016 Opportunities Fund, LP, (xiv) 67,314 shares held by New Science Ventures Fund III (Offshore), LP, and (xv) 27,835 shares held by NSV 2016 Opportunities Fund (Offshore), LP, collectively the NSV funds. NSV Partners III, LP, is the general partner of NSV 2018 New Horizons Fund LP, NSV Investments I, LP, NSV 2018 Opportunities Fund, LP, NSV 2019 Opportunities Fund, LP, NSV Growth Opportunities Fund, LP, NSV Investments III, LP, and NSV Investments II, LP. NSV Partners II, LLC, is the general partner of New Science Ventures Fund III, LP, New Science Ventures Fund III (Offshore), LP, NSV 2016 Opportunities Fund, LP, NSV 2016 Opportunities Fund (Offshore), LP, NSV 2017 Opportunities Fund, LP, and NSV Master Limited Partnership II, LP. the Reporting Person is the majority member and managing member of NSV Partners III GP, LLC, and may be deemed to have voting and dispositive power over the shares held by each entity of which NSV Partners III, LP is general partner. The Reporting Person disclaims beneficial ownership over the shares held by each of the NSV funds, except to the extent of his pecuniary interest therein. The Reporting Person is the majority member and managing member NSV Partners II, LLC, and may be deemed to have voting and dispositive power over the shares held by each entity of which NSV Partners II, LLC is general partner. /s/ Christopher Krueger, as Attorney-in-Fact 2022-11-09